Allergic Asthma Therapeutics Market to Garner a Valuation of US$ 8 Billion by 2027, at CAGR of 2.93% – Coherent Market Insights

Global Allergic Asthma Therapeutics Market, by Drug Type (Corticosteroids, Bronchodilators, Leukotriene modifiers, Immunotherapy, Biologics, and Others), By Route of Administration (Oral, Inhaled, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is expected to be valued at US$ 6,704.8 million in 2020 and is estimated to exhibit a CAGR of 2.93% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Fill the form for an exclusive sample of this report@ https://www.coherentmarketinsights.com/insight/request-sample/4019

In June 2017, Teva Pharmaceuticals Industries Ltd. received the U.S. FDA approval for its three products; ArmonAir, RespiClick, and AirDuo RespiClick. These are asthma inhalers for adult as well as adolescent patients suffering from asthma. ArmonAir and AirDuo are available by prescription to patients in the U.S. The approved strengths of ArmonAir is 232 mcg, 55 mcg, and 113 mcg, whereas, the approved strengths of AirDuo is 232/14 mcg, 55/14 mcg, and 113/14 mcg, and 55/14 mcg, directed as one inhalation twice daily.

Besides, Regeneron Pharmaceuticals, Inc. and Sanofi, in October 2018, received FDA approval for Dupixent (dupilumab), as an added maintenance therapy for patients with moderate-to-severe asthma.

Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/4019

Global Allergic Asthma Therapeutics Market – Impact of Coronavirus (Covid-19) Pandemic

The allergic asthma therapeutics market growth is hugely impacted by the sudden outbreak of COVID-19 all across the globe. Though the risk of asthma patients to be affected by COVID-19 is higher, authorities are taking utmost precaution to make the critical solutions (ventilators, inhalers) available to the patients. Supply for respiratory medications have not been affected due this pandemic.

The comprehensive version of the report will include COVID-19’s impact and the projected changes in the future outlook of the industry, by taking into the account the social, economic, political, and technological parameters.

Browse 24 Market Data Tables and 26 Figures spread through 170 Pages and in-depth TOC on Allergic Asthma Therapeutics Market, by Drug Type (Corticosteroids, Bronchodilators, Leukotriene modifiers, Immunotherapy, Biologics, and Others), by Route of Administration (Oral, Inhaled, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Forecast to 2027”

To know the latest trends and insights related to Allergic Asthma Therapeutics Market Press Release, click the link below: https://www.coherentmarketinsights.com/press-release/allergic-asthma-therapeutics-market-3289

Key players in the market are investing in research and development, focusing on geographical expansions, and joint ventures to strengthen their position in the global market. For instance, in May 2019, Singapore-based biopharma company, ASLAN Pharmaceuticals, revised its license agreement with CSL Limited (CSL) to have full global rights for developing, manufacturing, and commercializing ASLAN004 in all indications. ASLAN004 helps in triggering the symptoms of allergic asthma such as wheezing, shortness of breath, coughing, and exacerbations of the disease.

Key Takeaways of the Global Allergic Asthma Therapeutics Market:

• The allergic asthma therapeutics market is expected to exhibit a CAGR of 2.9% during the forecast period (2020-2027) owing to the rising number of respiratory diseases, and strategic collaborations and joint ventures among market players.
• Pipeline products from AstraZeneca, Sanofi, GSK, AB Science, Mundipharma, Shanghai Biomabs Pharmaceutical Co., Ltd., and Chiesi Farmaceutici among others would transcend the market scenario in near future, with their innovative single as well as combination asthma treatment products.
• Major players operating in the allergic asthma therapeutics market are Aslan Pharmaceuticals Pte. Ltd., Baxalta Incorporated, Axikin Pharmaceuticals, Chiesi Farmaceutici SpA, CSL Limited, Circassia Pharmaceuticals Plc, Fountain Biopharma Inc., Hydra Biosciences, GlaxoSmithKline Plc, Infinity Pharmaceuticals, Mabtech Limited, Kineta, Marinomed Biotechnologie Gmb, NeoPharm Co., Mycenax Biotech Inc., Panacea Biotec Limited, and Oxagen Limited.

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.